AU2020334069B2 - Method of treating KRAS-associated cancers - Google Patents

Method of treating KRAS-associated cancers

Info

Publication number
AU2020334069B2
AU2020334069B2 AU2020334069A AU2020334069A AU2020334069B2 AU 2020334069 B2 AU2020334069 B2 AU 2020334069B2 AU 2020334069 A AU2020334069 A AU 2020334069A AU 2020334069 A AU2020334069 A AU 2020334069A AU 2020334069 B2 AU2020334069 B2 AU 2020334069B2
Authority
AU
Australia
Prior art keywords
cancer
egfr
kras
compound
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020334069A
Other languages
English (en)
Other versions
AU2020334069A1 (en
Inventor
Mukesh K. Nyati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of AU2020334069A1 publication Critical patent/AU2020334069A1/en
Application granted granted Critical
Publication of AU2020334069B2 publication Critical patent/AU2020334069B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020334069A 2019-08-22 2020-08-20 Method of treating KRAS-associated cancers Active AU2020334069B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962890119P 2019-08-22 2019-08-22
US62/890,119 2019-08-22
PCT/US2020/047090 WO2021034992A1 (en) 2019-08-22 2020-08-20 Method of treating kras-associated cancers

Publications (2)

Publication Number Publication Date
AU2020334069A1 AU2020334069A1 (en) 2022-03-24
AU2020334069B2 true AU2020334069B2 (en) 2026-02-19

Family

ID=74660044

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020334069A Active AU2020334069B2 (en) 2019-08-22 2020-08-20 Method of treating KRAS-associated cancers

Country Status (11)

Country Link
US (1) US20220273643A1 (enExample)
EP (1) EP4017489B1 (enExample)
JP (1) JP7602272B2 (enExample)
KR (1) KR20220050143A (enExample)
CN (2) CN119454706A (enExample)
AU (1) AU2020334069B2 (enExample)
BR (1) BR112022003165A2 (enExample)
CA (1) CA3150759A1 (enExample)
IL (1) IL290454B2 (enExample)
MX (1) MX2022002108A (enExample)
WO (1) WO2021034992A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
KR20240016250A (ko) * 2021-04-02 2024-02-06 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료를 위한 병용요법
WO2023003417A1 (ko) * 2021-07-22 2023-01-26 국립암센터 Kras 돌연변이 특이적 저해제 및 이를 포함하는 암 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SI1913157T2 (sl) * 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
JP2013542960A (ja) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 脂肪酸シンターゼ阻害剤
US20140256767A1 (en) 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
AU2019223168B2 (en) * 2018-02-23 2024-09-12 The Regents Of The University Of Michigan EGFR dimer disruptors and use of the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof

Also Published As

Publication number Publication date
EP4017489A1 (en) 2022-06-29
EP4017489A4 (en) 2023-08-23
CA3150759A1 (en) 2021-02-25
KR20220050143A (ko) 2022-04-22
EP4017489C0 (en) 2025-05-07
BR112022003165A2 (pt) 2022-05-17
WO2021034992A1 (en) 2021-02-25
JP7602272B2 (ja) 2024-12-18
CN114286676A (zh) 2022-04-05
JP2022545005A (ja) 2022-10-24
IL290454B1 (en) 2025-08-01
MX2022002108A (es) 2022-03-17
IL290454B2 (en) 2025-12-01
US20220273643A1 (en) 2022-09-01
IL290454A (en) 2022-04-01
EP4017489B1 (en) 2025-05-07
AU2020334069A1 (en) 2022-03-24
CN119454706A (zh) 2025-02-18

Similar Documents

Publication Publication Date Title
EP4017489B1 (en) Dgd1202 for use in the treatment of kras-mutated cancers
US11999731B2 (en) EGFR dimer disruptors and use of the same
CN103635192B (zh) Akt抑制剂化合物和化疗剂的组合以及使用方法
CN115397413A (zh) Egfr、kras、braf和其他靶标的抑制剂及其用途
JP2023515689A (ja) Ｅｇｆｒ、ｋｒａｓ、ｂｒａｆ、及び他の標的の阻害剤、並びにその使用
JP2021121611A (ja) アピリモドを用いる癌の処置方法
JP7123806B2 (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
JP2016535756A (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
CN110891576A (zh) 使用包含parp抑制剂、替莫唑胺和/或放射疗法的组合治疗癌症
KR20160126984A (ko) 아필리모드 조성물 및 이를 사용하기 위한 방법
TW202535405A (zh) 用於藉由增強數類已核准藥物的作用以治療癌症之alc1抑制劑
HK40072817A (en) Method of treating kras-associated cancers
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
EA048458B1 (ru) Способы комбинированной терапии
EA042609B1 (ru) Ингибиторы димеризации egfr и их использование
TW201825092A (zh) 使用包含吲哚嗪并[6, 7-b]吲哚衍生物的醫藥組合物或組合治療小細胞肺癌的方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)